文献速递其他结缔组织病

抗Ro52与抗Ro60血清学分层揭示原发性干燥病不同系统表型

Serological Stratification by Anti-Ro52 and Anti-Ro60 Profiles Reveals Distinct Systemic Phenotypes in Primary Sjögren's Disease.
PubMed 文献 · Semin Arthritis Rheum · 2026-02-10

该回顾性研究纳入725例原发性干燥病(pSjD)患者,按抗Ro52/Ro60状态分为四组,采用多因素logistic回归分析其与系统受累的关联。结果显示抗Ro52阳性组ESSDAI评分更高,双阳性与肾脏、皮肤受累、高球蛋白血症和低补体独立相关,而Ro52+Ro60-特异地与间质性肺病(ILD)相关,且抗Ro52与抗Ro60对高球蛋白血症存在协同交互作用。

要点

  • 抗Ro52阳性pSjD患者ESSDAI评分显著更高,提示疾病更严重。
  • 双阳性(Ro52+Ro60+)独立关联肾脏、皮肤受累、高球蛋白血症和低补体。
  • Ro52+Ro60-特异地与ILD相关,双阳性对高球蛋白血症存在协同交互。

核心结论

  • 抗Ro52和抗Ro60血清学谱可区分pSjD的不同临床亚群。
  • 抗Ro52阳性与更严重的疾病相关,双阳性定义多器官受累和免疫过度激活的独特亚组。
  • 全面检测抗Ro抗体具有临床实用价值。

研究设计与样本

  • 回顾性研究,纳入725例原发性干燥病患者,按抗Ro52/Ro60状态分为四组。
  • 采用多因素logistic回归(经LASSO校正混杂因素)评估独立关联。
  • 计算RERI、AP和SI以确定抗Ro52与抗Ro60的相加交互作用。

主要发现

  • 队列中21.5%为Ro52-Ro60-,17.7%为Ro52+Ro60-,10.2%为Ro52-Ro60+,50.6%为Ro52+Ro60+。
  • 抗Ro52阳性组(Ro52+Ro60-和Ro52+Ro60+)ESSDAI评分显著更高。
  • 校正后,Ro52+Ro60+与肾脏受累(OR=5.53,95%CI 2.56-11.97,p<0.001)、皮肤受累(OR=2.49,95%CI 1.08-5.75,p=0.032)、高球蛋白血症(OR=5.19,95%CI 2.96-9.10,p<0.001)和低补体水平(OR=1.70,95%CI 1.07-2.71,p=0.025)独立相关。
  • Ro52+Ro60-特异地与间质性肺病相关(OR=4.17,95%CI 2.33-7.46,p<0.001)。
  • 抗Ro52与抗Ro60对高球蛋白血症存在显著协同交互作用(校正RERI=3.00,95%CI 0.87-5.14;AP=0.58,95%CI 0.31-0.84;SI=3.52,95CI 1.04-11.94)。

关键数值与推荐

  • 双阳性(Ro52+Ro60+)与肾脏受累OR=5.53(95%CI 2.56-11.97,p<0.001)。
  • 双阳性与皮肤受累OR=2.49(95%CI 1.08-5.75,p=0.032)。
  • 双阳性与高球蛋白血症OR=5.19(95%CI 2.96-9.10,p<0.001)。
  • 双阳性与低补体水平OR=1.70(95%CI 1.07-2.71,p=0.025)。
  • Ro52+Ro60-与ILD的OR=4.17(95%CI 2.33-7.46,p<0.001)。

临床怎么用

  • 对pSjD患者应全面检测抗Ro52和抗Ro60以进行血清学分层。
  • 抗Ro52阳性尤其双阳性患者需警惕肾脏、皮肤受累、高球蛋白血症和低补体,应加强系统评估。
  • Ro52+Ro60-患者应关注间质性肺病筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-Ro52 and anti-Ro60 antibodies are key serological markers for primary Sjögren's disease (pSjD), yet their association with specific clinical phenotypes remains unclear. This study aimed to define the predictive value of anti-Ro profiles for systemic involvement in pSjD. METHODS: In this retrospective study of 725 pSjD patients, we categorized patients into four subgroups based on their anti-Ro52/Ro60 status. Multivariable logistic regression, adjusted for confounders via LASSO, assessed independent associations. Relative excess risk due to interaction (RERI), attributable proportion of interaction (AP) and synergy index (SI) were calculated to determine the additive interaction between anti-Ro52 and anti-Ro60. RESULTS: The cohort consisted of 21.5% Ro52-Ro60-, 17.7% Ro52+Ro60-, 10.2% Ro52-Ro60+, and 50.6% Ro52+Ro60+ patients. Anti-Ro52 positive groups (Ro52+Ro60- and Ro52+Ro60+) exhibited significantly higher ESSDAI scores. After adjustment, the Ro52+Ro60+ profile was independently associated with renal involvement (OR=5.53, 95%CI 2.56-11.97, p<0.001), cutaneous involvement (OR=2.49, 95%CI 1.08-5.75, p=0.032), hyperglobulinemia (OR=5.19, 95%CI 2.96-9.10, p<0.001), and low complement levels (OR=1.70, 95%CI 1.07-2.71, p=0.025). In contrast, the Ro52+Ro60- profile was specifically linked to interstitial lung disease (ILD) (OR=4.17, 95%CI 2.33-7.46, p<0.001). A significant synergistic interaction between anti-Ro52 and anti-Ro60 was identified for hyperglobulinemia (adjusted RERI=3.00, 95%CI 0.87-5.14; AP=0.58, 95%CI 0.31-0.84; SI=3.52, 95CI 1.04-11.94). CONCLUSIONS: Anti-Ro52 and anti-Ro60 profiles delineate distinct clinical subsets of pSjD. Anti-Ro52 positivity is associated with greater disease severity, while double positivity defines a unique subgroup with multi-organ involvement and immune hyperactivation, highlighting the clinical utility of comprehensive anti-Ro testing.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Zhang L, Lv L, et al. Serological Stratification by Anti-Ro52 and Anti-Ro60 Profiles Reveals Distinct Systemic Phenotypes in Primary Sjögren's Disease. Semin Arthritis Rheum. 2026. PMID: 41707292. doi:10.1016/j.semarthrit.2026.152942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。